Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Lumos Pharma management to meet virtually with Cantor Fitzgerald » 04:55
01/18/21
01/18
04:55
01/18/21
04:55
LUMO

Lumos Pharma

$21.30 /

-0.45 (-2.07%)

Virtual Meeting to be…

Virtual Meeting to be held on January 18 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
LUMO Lumos Pharma
$21.30 /

-0.45 (-2.07%)

LUMO Lumos Pharma
$21.30 /

-0.45 (-2.07%)

12/03/20
Fly Intel: Top five analyst initiations
12/03/20 Cantor Fitzgerald
Lumos Pharma initiated with an Overweight at Cantor Fitzgerald
12/02/20 Cantor Fitzgerald
Lumos Pharma initiated with an Overweight at Cantor Fitzgerald
08/25/20 Piper Sandler
Lumos Pharma initiated with an Overweight at Piper Sandler
LUMO Lumos Pharma
$21.30 /

-0.45 (-2.07%)

LUMO Lumos Pharma
$21.30 /

-0.45 (-2.07%)

LUMO Lumos Pharma
$21.30 /

-0.45 (-2.07%)

Conference/Events
Lumos Pharma management to meet virtually with Cantor Fitzgerald » 10:08
01/15/21
01/15
10:08
01/15/21
10:08
LUMO

Lumos Pharma

$21.78 /

+0.03 (+0.14%)

Virtual Meeting to be…

Virtual Meeting to be held on January 18 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
LUMO Lumos Pharma
$21.78 /

+0.03 (+0.14%)

LUMO Lumos Pharma
$21.78 /

+0.03 (+0.14%)

12/03/20
Fly Intel: Top five analyst initiations
12/03/20 Cantor Fitzgerald
Lumos Pharma initiated with an Overweight at Cantor Fitzgerald
12/02/20 Cantor Fitzgerald
Lumos Pharma initiated with an Overweight at Cantor Fitzgerald
08/25/20 Piper Sandler
Lumos Pharma initiated with an Overweight at Piper Sandler
LUMO Lumos Pharma
$21.78 /

+0.03 (+0.14%)

LUMO Lumos Pharma
$21.78 /

+0.03 (+0.14%)

LUMO Lumos Pharma
$21.78 /

+0.03 (+0.14%)

Initiation
Fly Intel: Top five analyst initiations » 09:55
12/03/20
12/03
09:55
12/03/20
09:55
AMTX

Aemetis

$3.00 /

+0.72 (+31.58%)

, GBT

Global Blood Therapeutics

$45.68 /

+0.93 (+2.08%)

, LUMO

Lumos Pharma

$16.00 /

+0.93 (+6.17%)

, SWKH

SWK Holdings

$13.13 /

-0.05 (-0.38%)

, MP

MP Materials

$21.10 /

+0.18 (+0.86%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aemetis (AMTX) initiated with a Buy at H.C. Wainwright. 2. Global Blood Therapeutics (GBT) initiated with an Outperform at RBC Capital. 3. Lumos Pharma (LUMO) initiated with an Overweight at Cantor Fitzgerald. 4. SWK Holdings (SWKH) initiated with a Buy at Maxim. 5. MP Materials (MP) initiated with an Outperform at Northland. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
SWKH SWK Holdings
$13.13 /

-0.05 (-0.38%)

LUMO Lumos Pharma
$16.00 /

+0.93 (+6.17%)

GBT Global Blood Therapeutics
$45.68 /

+0.93 (+2.08%)

AMTX Aemetis
$3.00 /

+0.72 (+31.58%)

AMTX Aemetis
$3.00 /

+0.72 (+31.58%)

12/03/20 H.C. Wainwright
Aemetis initiated with a Buy at H.C. Wainwright
GBT Global Blood Therapeutics
$45.68 /

+0.93 (+2.08%)

12/03/20 RBC Capital
Global Blood Therapeutics initiated with an Outperform at RBC Capital
11/18/20 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $120 from $133 at Cantor Fitzgerald
11/09/20 Truist
Global Blood Therapeutics price target lowered to $55 from $78 at Truist
11/06/20 Raymond James
Global Blood Therapeutics downgraded to Market Perform from Outperform at Raymond James
LUMO Lumos Pharma
$16.00 /

+0.93 (+6.17%)

12/03/20 Cantor Fitzgerald
Lumos Pharma initiated with an Overweight at Cantor Fitzgerald
12/02/20 Cantor Fitzgerald
Lumos Pharma initiated with an Overweight at Cantor Fitzgerald
08/25/20 Piper Sandler
Lumos Pharma initiated with an Overweight at Piper Sandler
08/17/20 Roth Capital
Lumos Pharma assumed with a Buy at Roth Capital
SWKH SWK Holdings
$13.13 /

-0.05 (-0.38%)

12/03/20 Maxim
SWK Holdings initiated with a Buy at Maxim
05/27/20
SWK Holdings initiated with a Buy at Dougherty
MP MP Materials
$21.10 /

+0.18 (+0.86%)

12/03/20 Northland
MP Materials initiated with an Outperform at Northland
12/01/20 Deutsche Bank
MP Materials initiated with a Buy at Deutsche Bank
SWKH SWK Holdings
$13.13 /

-0.05 (-0.38%)

LUMO Lumos Pharma
$16.00 /

+0.93 (+6.17%)

GBT Global Blood Therapeutics
$45.68 /

+0.93 (+2.08%)

LUMO Lumos Pharma
$16.00 /

+0.93 (+6.17%)

GBT Global Blood Therapeutics
$45.68 /

+0.93 (+2.08%)

MP MP Materials
$21.10 /

+0.18 (+0.86%)

LUMO Lumos Pharma
$16.00 /

+0.93 (+6.17%)

AMTX Aemetis
$3.00 /

+0.72 (+31.58%)

Initiation
Lumos Pharma initiated with an Overweight at Cantor Fitzgerald » 07:05
12/03/20
12/03
07:05
12/03/20
07:05
LUMO

Lumos Pharma

$15.50 /

-0.43 (-2.70%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Charles Duncan initiated coverage of Lumos Pharma with an Overweight rating and $32 price target. Duncan believes Lumos' LUM-201, which has orphan designation in the US/EU, leverages a differentiated mechanism of action and administration paradigm relative to standard of care recombinant human growth hormone to improve therapy options for pediatric growth hormone deficiency. The analyst also believes that LUM-201 may demonstrate potentially clinical utility in other rare endocrine disorders, making it a pipeline in a product.

ShowHide Related Items >><<
LUMO Lumos Pharma
$15.50 /

-0.43 (-2.70%)

LUMO Lumos Pharma
$15.50 /

-0.43 (-2.70%)

12/02/20 Cantor Fitzgerald
Lumos Pharma initiated with an Overweight at Cantor Fitzgerald
08/25/20 Piper Sandler
Lumos Pharma initiated with an Overweight at Piper Sandler
08/17/20 Roth Capital
Lumos Pharma assumed with a Buy at Roth Capital
08/04/20 H.C. Wainwright
Lumos Pharma initiated with a Buy at H.C. Wainwright
LUMO Lumos Pharma
$15.50 /

-0.43 (-2.70%)

LUMO Lumos Pharma
$15.50 /

-0.43 (-2.70%)

LUMO Lumos Pharma
$15.50 /

-0.43 (-2.70%)

Initiation
Lumos Pharma initiated with an Overweight at Cantor Fitzgerald » 16:10
12/02/20
12/02
16:10
12/02/20
16:10
LUMO

Lumos Pharma

$15.50 /

-0.43 (-2.70%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Charles Duncan initiated coverage of Lumos Pharma with an Overweight rating and $32 price target.

ShowHide Related Items >><<
LUMO Lumos Pharma
$15.50 /

-0.43 (-2.70%)

LUMO Lumos Pharma
$15.50 /

-0.43 (-2.70%)

08/25/20 Piper Sandler
Lumos Pharma initiated with an Overweight at Piper Sandler
08/17/20 Roth Capital
Lumos Pharma assumed with a Buy at Roth Capital
08/04/20 H.C. Wainwright
Lumos Pharma initiated with a Buy at H.C. Wainwright
05/01/20
Fly Intel: Top five analyst initiations
LUMO Lumos Pharma
$15.50 /

-0.43 (-2.70%)

LUMO Lumos Pharma
$15.50 /

-0.43 (-2.70%)

LUMO Lumos Pharma
$15.50 /

-0.43 (-2.70%)

Over a quarter ago
Hot Stocks
Lumos initiated Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in PGHD » 16:54
11/10/20
11/10
16:54
11/10/20
16:54
LUMO

Lumos Pharma

$14.75 /

-0.05 (-0.34%)

Lumos Pharma announced…

Lumos Pharma announced the initiation of its Phase 2b OraGrowtH210 trial evaluating oral LUM-201 in pediatric growth hormone deficiency, PGHD, patients. The trial will evaluate three dose levels of LUM-201 in PGHD patients against a comparator arm of standard-of-care injectable growth hormone therapy. Dosing will be administered over six months, with annualized growth height velocity as the primary clinical outcome measure. The purpose of this trial will be to prospectively confirm our Predictive Enrichment Marker (PEM) strategy and to identify the optimal dose of LUM-201 to be used in a registration trial. The Company anticipates data read out for the OraGrowtH210 Trial mid-year 2022.

ShowHide Related Items >><<
LUMO Lumos Pharma
$14.75 /

-0.05 (-0.34%)

LUMO Lumos Pharma
$14.75 /

-0.05 (-0.34%)

08/25/20 Piper Sandler
Lumos Pharma initiated with an Overweight at Piper Sandler
08/17/20 Roth Capital
Lumos Pharma assumed with a Buy at Roth Capital
08/04/20 H.C. Wainwright
Lumos Pharma initiated with a Buy at H.C. Wainwright
05/01/20
Fly Intel: Top five analyst initiations
LUMO Lumos Pharma
$14.75 /

-0.05 (-0.34%)

LUMO Lumos Pharma
$14.75 /

-0.05 (-0.34%)

LUMO Lumos Pharma
$14.75 /

-0.05 (-0.34%)

Earnings
Lumos Pharma reports Q3 EPS 21c, consensus (64c) » 16:53
11/10/20
11/10
16:53
11/10/20
16:53
LUMO

Lumos Pharma

$14.75 /

-0.05 (-0.34%)

Lumos Pharma ended the…

Lumos Pharma ended the quarter on September 30, with cash and cash equivalents totaling $105.6 million compared to Lumos Pharma prior to its merger with NewLink Genetics cash of $5.0 million December 31, 2019 and pro forma December 31, 2019 cash of $95.5 million, inclusive of NewLink Genetics. The Company expects its cash on hand is sufficient to fund current operations through the read-out of our Phase 2b OraGrowtH210 Trial and completion of the OraGrowtH212 Trial. "This past quarter was marked by significant achievements leading to the initiation of our Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency patients and the previously announced sale of our PRV in July," commented Rick Hawkins, Chairman, CEO and President of Lumos Pharma. "We are thrilled to advance our LUM-201 program and look forward to building upon this momentum as we continue our efforts to expand our business and pipeline."

ShowHide Related Items >><<
LUMO Lumos Pharma
$14.75 /

-0.05 (-0.34%)

LUMO Lumos Pharma
$14.75 /

-0.05 (-0.34%)

08/25/20 Piper Sandler
Lumos Pharma initiated with an Overweight at Piper Sandler
08/17/20 Roth Capital
Lumos Pharma assumed with a Buy at Roth Capital
08/04/20 H.C. Wainwright
Lumos Pharma initiated with a Buy at H.C. Wainwright
05/01/20
Fly Intel: Top five analyst initiations
LUMO Lumos Pharma
$14.75 /

-0.05 (-0.34%)

LUMO Lumos Pharma
$14.75 /

-0.05 (-0.34%)

Options
Six new option listings and ten option delistings on October 19th » 08:30
10/19/20
10/19
08:30
10/19/20
08:30
BNL

Broadstone Net Lease

$17.00 /

+0.22 (+1.31%)

, KALV

KalVista

$16.20 /

+0.82 (+5.33%)

, STEP

Stepstone Group

$26.27 /

+0.32 (+1.23%)

, WWR

Westwater Resources

$5.75 /

-0.36 (-5.89%)

, ICD

Independence Contract Drilling

$2.58 /

-0.14 (-5.15%)

, LUMO

Lumos Pharma

$14.22 /

-0.02 (-0.14%)

, MCEP

Mid-Con Energy

$2.18 /

+ (+0.00%)

, SPHS

Sophiris Bio

$0.00 /

+ (+0.00%)

, SUP

Superior Industries

$1.36 /

-0.04 (-2.86%)

, WINMQ

Windstream

$0.34 /

+ (+0.00%)

New option listings for…

New option listings for October 19th include Broadstone Net Lease Inc (Class A Stock) (BNL), KalVista (KALV), Oshares Global Internet Giants ETF (OGIG), SPDR Blackstone GSO Senior Loan ETF (SRLN), StepStone Group Inc (Class A Stock) (STEP), and Westwater Resources Inc (WWR). Option delistings effective October 19th include Centric Brands Inc (CTRCQ), Endologix Inc (ELGXQ), Independence Contract Drilling (ICD), Internap Corporation (INAPQ), Lumos Pharma (LUMO), Mid Con Energy (MCEP), Sophiris Bio Inc (SPHS), Stage Stores Inc (SSINQ), Superior Industries (SUP), and Windstream Holdings Inc (WINMQ).

ShowHide Related Items >><<
WWR Westwater Resources
$5.75 /

-0.36 (-5.89%)

WINMQ Windstream
$0.34 /

+ (+0.00%)

SUP Superior Industries
$1.36 /

-0.04 (-2.86%)

SPHS Sophiris Bio
$0.00 /

+ (+0.00%)

MCEP Mid-Con Energy
$2.18 /

+ (+0.00%)

LUMO Lumos Pharma
$14.22 /

-0.02 (-0.14%)

KALV KalVista
$16.20 /

+0.82 (+5.33%)

ICD Independence Contract Drilling
$2.58 /

-0.14 (-5.15%)

BNL Broadstone Net Lease
$17.00 /

+0.22 (+1.31%)

10/12/20 Capital One
Broadstone Net Lease initiated with an Overweight at Capital One
10/12/20 JPMorgan
Broadstone Net Lease initiated with an Overweight at JPMorgan
10/12/20 Morgan Stanley
Broadstone Net Lease initiated with an Overweight at Morgan Stanley
10/12/20 Truist
Broadstone Net Lease initiated with a Buy at Truist
KALV KalVista
$16.20 /

+0.82 (+5.33%)

10/15/20 Roth Capital
KalVista updates highlight potential to become HAE leader, says Roth Capital
06/15/20
Fly Intel: Top five analyst initiations
06/15/20 H.C. Wainwright
KalVista initiated with a Buy at H.C. Wainwright
03/10/20 Roth Capital
Roth Capital sees good odds for KalVista into Q2 KVD900 readout
STEP Stepstone Group
$26.27 /

+0.32 (+1.23%)

10/12/20 JPMorgan
Stepstone Group initiated with a Neutral at JPMorgan
10/12/20 Morgan Stanley
Stepstone Group initiated with an Overweight at Morgan Stanley
10/12/20 UBS
Stepstone Group initiated with a Buy at UBS
10/12/20 Barclays
Stepstone Group initiated with an Equal Weight at Barclays
WWR Westwater Resources
$5.75 /

-0.36 (-5.89%)

ICD Independence Contract Drilling
$2.58 /

-0.14 (-5.15%)

05/11/20 B. Riley Securities
Independence Contract Drilling downgraded to Neutral from Buy at B. Riley FBR
03/11/20 Tudor Pickering
Independence Contract Drilling downgraded to Hold from Buy at Tudor Pickering
03/09/20 Evercore ISI
Independence Contract Drilling downgraded to In Line from Outperform at Evercore ISI
LUMO Lumos Pharma
$14.22 /

-0.02 (-0.14%)

08/25/20 Piper Sandler
Lumos Pharma initiated with an Overweight at Piper Sandler
08/17/20 Roth Capital
Lumos Pharma assumed with a Buy at Roth Capital
08/04/20 H.C. Wainwright
Lumos Pharma initiated with a Buy at H.C. Wainwright
05/01/20
Fly Intel: Top five analyst initiations
MCEP Mid-Con Energy
$2.18 /

+ (+0.00%)

SPHS Sophiris Bio
$0.00 /

+ (+0.00%)

10/21/19 H.C. Wainwright
Sophiris trial greenlight from FDA removes a key overhang, says H.C. Wainwright
SUP Superior Industries
$1.36 /

-0.04 (-2.86%)

03/19/20 B. Riley Securities
B. Riley FBR downgrades four names with exposure to auto manufacturers
03/19/20 B. Riley Securities
Superior Industries downgraded to Neutral from Buy at B. Riley FBR
01/09/20 Benchmark
Benchmark starts Superior Industries at Hold on sub-par performance, high debt
01/09/20 Benchmark
Superior Industries initiated with a Hold at Benchmark
WINMQ Windstream
$0.34 /

+ (+0.00%)

03/03/20 Raymond James
Uniti Group upgraded to Outperform from Market Perform at Raymond James
KALV KalVista
$16.20 /

+0.82 (+5.33%)

ICD Independence Contract Drilling
$2.58 /

-0.14 (-5.15%)

  • 16
    Sep
  • 17
    Sep
LUMO Lumos Pharma
$14.22 /

-0.02 (-0.14%)

BNL Broadstone Net Lease
$17.00 /

+0.22 (+1.31%)

Initiation
Lumos Pharma initiated with an Overweight at Piper Sandler » 16:16
08/25/20
08/25
16:16
08/25/20
16:16
LUMO

Lumos Pharma

$14.99 /

+0.14 (+0.94%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Lumos Pharma (LUMO) with an Overweight rating and $26 price target, which presents 72% potential upside. Even with the recent sale of its Priority Review Voucher to Merck (MRK) for $60M on July 27, Lumos continues to trade below cash ahead of the end of 2020 Phase 2b initiation for its lead asset LUM-201, an oral treatment for pediatric growth hormone deficiency, Rahimi tells investors in a research note.

ShowHide Related Items >><<
LUMO Lumos Pharma
$14.99 /

+0.14 (+0.94%)

LUMO Lumos Pharma
$14.99 /

+0.14 (+0.94%)

08/17/20 Roth Capital
Lumos Pharma assumed with a Buy at Roth Capital
08/04/20 H.C. Wainwright
Lumos Pharma initiated with a Buy at H.C. Wainwright
05/01/20
Fly Intel: Top five analyst initiations
05/01/20 Roth Capital
Lumos Pharma initiated with a Buy at Roth Capital
LUMO Lumos Pharma
$14.99 /

+0.14 (+0.94%)

Initiation
Lumos Pharma assumed with a Buy at Roth Capital » 08:02
08/17/20
08/17
08:02
08/17/20
08:02
LUMO

Lumos Pharma

$14.94 /

-0.46 (-2.99%)

Roth Capital analyst…

Roth Capital analyst Elemer Piros assumed coverage of Lumos Pharma with a Buy rating and $51 price target. The analyst believes that Lumos' LUM-201 oral growth hormone sercretagogue is well positioned to achieve significant market share in pediatric growth hormone deficiency, a therapeutic area that is dominated by injectables.

ShowHide Related Items >><<
LUMO Lumos Pharma
$14.94 /

-0.46 (-2.99%)

LUMO Lumos Pharma
$14.94 /

-0.46 (-2.99%)

08/04/20 H.C. Wainwright
Lumos Pharma initiated with a Buy at H.C. Wainwright
05/01/20
Fly Intel: Top five analyst initiations
05/01/20 Roth Capital
Lumos Pharma initiated with a Buy at Roth Capital
04/16/20 Jefferies
Lumos Pharma initiated with a Buy at Jefferies
LUMO Lumos Pharma
$14.94 /

-0.46 (-2.99%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.